In　our　research　on　novel　anticancer　agents,　a　series　of　N-6-hydrazone　purine　derivatives　were　designed　and　synthesized　by　analysis　of　a　pharmacophore　model　for　ATP-competitive　inhibitors.　The　activities　screening　results　showed　that　N-6-hydrazone　purine　derivatives　21　and　26　not　only　showed　potential　antiproliferative　activity　against　the　A549　and　MCF-7　cell　lines　comparable　to　Vandetanib　as　a　positive　control　but　also　had　moderate　antiplatelet　aggregation　activity.　In　order　to　investigate　the　possible　targets,　a　molecular　docking　study　was　carried　out　on　the　fourteen　kinases　associated　with　anticancer　and　antiplatelet　aggregation　activities.　The　results　indicated　that　compounds　21　and　26　had　the　potential　activity　to　target　VEGFR-2,　PI3K　alpha,　EGFR,　and　HER2　kinases.　The　inhibition　of　the　kinases　assay　showed　that　compound　26　could　target　VEGFR-2,　PI3K　alpha,　and　EGFR　(IC50　=　0.822,　3.040　and　6.625　mu　M).　All　results　indicated　that　compound　26　will　be　an　encouraging　framework　as　potential　new　multi-target　anticancer　agent　with　potential　antiplatelet　aggregation　activity.